Loading clinical trials...
Loading clinical trials...
Vascular Fingerprint to Identify Patients at Risk for Arterial Cardiovascular Events Within the First Year After Start of Cisplatin-based Chemotherapy for Testicular Cancer: a Validation Study
Conditions
Locations
5
Netherlands
Nederlands Kanker Instituut - Antoni van Leeuwenhoek ziekenhuis (NKI-AVL)
Amsterdam, Netherlands
University Medical Center Groningen (UMCG)
Groningen, Netherlands
Maastricht University Medical Center (MUMC)
Maastricht, Netherlands
Instituto Portuges de Oncologia Francisco Gentil (IPOLFG)
Lisbon, Portugal
UniversitatsSpital Zurich
Zurich, Switzerland
Start Date
October 1, 2015
Primary Completion Date
April 1, 2024
Completion Date
April 1, 2024
Last Updated
May 17, 2024
NCT07218913
NCT07106827
NCT06814496
NCT06954233
NCT06673329
NCT05670938
Lead Sponsor
University Medical Center Groningen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions